No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
205 |
4. Check minimum number of eventsNone |
205 |
5. Include endpointsNone |
205 |
6. Filter based on genotype QC (FinnGen only) |
205 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified disorders of binocular movement
based on the number of shared cases.
Similar with more cases:
- Other disorders of binocular movement
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1678 | 882 | 788 |
| Only index persons | 1432 | 767 | 665 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 25.62 | 31.82 | 18.49 |
| Only index persons | 29.45 | 33.84 | 24.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 205 | 134 | 71 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.03 |
| Median age at first event (years) | 38.48 | 35.21 | 44.66 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 175
- Matched controls
- 1749
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
92.0
80
*
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
+∞
76.9
68
*
H53.2
ICD-10 Finland
Diplopia
49.1
24.5
29
7
3788X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Other disorders of binocular eye movements
+∞
23.5
22
*
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
99.8
16.9
18
*
H50.2
ICD-10 Finland
Vertical strabismus
+∞
14.8
14
*
H50.31
ICD-10 Finland
Intermittent exotropia
+∞
13.7
13
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
13.7
13
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.1
13.6
39
79
H50.30
ICD-10 Finland
Intermittent esotropy
+∞
11.6
11
*
H50.0
ICD-10 Finland
Convergent concomitant strabismus
128.1
11.6
12
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.7
11.3
33
68
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.9
9.9
33
79
XA800
NOMESCO Finland
Neuropsychological investigation
6.4
9.7
25
44
H50.52
ICD-10 Finland
Exophoria
+∞
9.5
9
*
L28
ICPC
Limited function/disability (L)
4.3
9.2
35
96
R4110
NOMESCO Finland
Physiotherapy
3.0
9.1
66
295
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
8.4
8
*
F83
ICD-10 Finland
Mixed specific developmental disorders
18.3
8.2
12
7
TAB00
NOMESCO Finland
Lumbar puncture
6.3
7.8
20
35
G43.3
ICD-10 Finland
Complicated migraine
47.1
7.8
9
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.2
7.5
28
75
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
7.3
7
*
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
7.3
7
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.9
7.2
30
89
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.2
7.0
39
145
G35
ICD-10 Finland
Multiple sclerosis
17.5
6.8
10
6
H53.0
ICD-10 Finland
Amblyopia ex anopsia
41.7
6.8
8
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
41.7
6.8
8
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
23.6
6.7
9
*
AA1AD
NOMESCO Finland
CT of head and brain
2.9
6.5
43
179
H47.7
ICD-10 Finland
Disorder of visual pathways, unspecified
72.4
6.5
7
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
72.4
6.5
7
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.3
6.4
23
60
R1260
NOMESCO Finland
Evaluation of communicative skills
18.9
6.3
9
5
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
27.8
6.3
8
*
0148
NOMESCO Finland
NA
+∞
6.3
6
*
3789X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Unspecified disorder of eye movements
+∞
6.3
6
*
H50.8
ICD-10 Finland
Other specified strabismus
+∞
6.3
6
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
6.3
6
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
6.3
6
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.2
6.3
23
61
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.2
6.2
13
17
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
14
12.31
15.50
1.0
1.1
—
—
—
0
0
16
15
11.49
14.83
1.0
1.1
—
—
—
0
0
16
15
11.49
14.83
1.0
1.1
—
—
—
0
0
25
44
6.33
14.05
2.1
2.1
58.3
2.5
e6/l
0.65
19
30
25
44
6.33
14.05
2.2
2.2
320.2
37.9
e6/l
0.46
19
34
14
13
11.49
12.99
2.7
1.2
—
—
—
0
0
11
10
11.57
10.24
1.0
1.0
—
—
—
0
0
85
437
2.61
9.90
3.6
2.6
0.3
0.3
e6/l
0.06
65
305
13
8
17.23
8.67
2.6
1.3
—
—
—
0
0
116
723
2.39
8.56
8.7
7.2
1.2
1.2
mmol/l
0.30
102
629
92
541
2.27
7.51
4.4
2.8
—
—
—
0
0
105
665
2.19
7.01
7.9
7.3
1.2
1.2
mmol/l
0.76
97
607
21
63
3.60
6.19
1.4
1.5
33.2
39.3
u/l
0.76
21
57
53
265
2.35
6.16
3.3
2.5
0.7
0.8
e6/l
0.13
27
139
51
259
2.29
5.69
3.5
2.6
1.0
3.1
e6/l
1.98
25
135
126
906
2.01
5.50
6.2
5.4
6.3
6.5
mmol/l
0.33
117
831
33
142
2.58
5.25
2.0
2.4
37.9
28.1
u/l
0.70
25
120
135
1011
1.98
5.05
12.9
8.7
3.8
4.0
e9/l
0.61
120
883
22
78
3.04
5.00
4.2
7.6
130.7
129.7
g/l
0.07
22
78
8
7
11.82
4.82
1.0
1.3
11.6
10.9
umol/l
—
8
7
8
8
10.34
4.56
1.0
1.1
—
—
—
0
0
41
208
2.21
4.53
1.8
1.6
901.1
1229.0
nmol/l
1.43
32
157
8
9
9.19
4.32
1.1
1.3
1.7
1.7
mmol/l
—
8
9
81
535
1.85
4.25
1.9
1.8
96.4
94.7
pmol/l
0.10
45
272
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
11
7.51
3.89
1.0
1.2
—
—
—
0
0
15
49
3.22
3.89
1.5
2.1
2.0
4.9
iu/l
—
5
19
31
151
2.24
3.76
9.2
10.1
0.6
1.0
mmol/l
0.21
22
118
13
40
3.40
3.69
2.3
1.6
—
—
—
0
0
108
805
1.72
3.59
4.6
3.2
0.0
0.0
estimate
0.00
16
156
10
27
3.84
3.40
1.3
1.2
—
—
—
0
0
104
778
1.68
3.33
6.1
6.2
10.8
11.5
umol/l
0.28
98
737
57
365
1.78
3.18
2.0
2.1
—
—
—
0
0
105
801
1.64
3.03
7.4
4.7
0.0
0.0
estimate
0.00
16
160
153
1288
1.74
2.98
4.9
4.0
14.7
14.5
pmol/l
0.51
143
1190
137
1124
1.66
2.90
2.8
2.9
35.2
40.7
u/l
0.39
130
1073
16
65
2.59
2.87
6.6
3.3
45.9
51.7
%
0.34
16
65
26
133
2.09
2.80
12.5
10.8
24.8
25.0
mmol/l
0.07
26
133
17
73
2.45
2.73
3.5
7.0
1.0
1.3
%
0.59
17
73
34
196
1.88
2.64
2.8
2.1
2.3
2.5
g/l
1.06
34
177
104
813
1.57
2.57
5.0
3.3
0.0
0.0
estimate
0.00
14
153
29
161
1.93
2.51
2.1
1.9
—
—
—
0
0
28
157
1.91
2.36
2.0
1.9
—
—
—
0
0
139
1174
1.57
2.35
7.9
6.3
88.1
82.2
u/l
0.36
130
1110
11
41
2.78
2.31
1.3
1.6
—
—
—
0
0
16
73
2.29
2.27
2.3
1.6
—
—
—
0
0
183
1671
1.89
2.12
21.1
12.8
3.9
3.9
mmol/l
0.26
178
1620
87
679
1.49
2.04
2.8
2.4
78.4
73.4
nmol/l
0.72
81
614
9
32
2.89
2.02
1.2
1.3
—
—
—
0
0
9
32
2.89
2.02
1.2
1.3
—
—
—
0
0
96
766
1.48
2.01
3.9
3.8
—
—
—
0
0
5
11
4.63
1.95
4.0
1.7
—
—
—
0
0
51
358
1.57
1.95
2.4
2.1
1.1
1.3
mg/l
0.18
41
271
34
216
1.69
1.92
2.9
2.1
12.8
14.4
umol/l
0.62
34
195
9
34
2.72
1.89
1.2
1.1
—
—
—
0
0
177
1615
1.70
1.86
23.8
13.1
38.2
40.1
%
1.99
145
1286
54
392
1.51
1.76
2.4
2.3
2.7
2.7
mg/l
0.08
49
329
6
18
3.40
1.76
1.3
1.1
—
—
nmol/l
—
0
0
171
1558
1.59
1.68
5.7
4.6
1.7
1.9
mu/l
1.81
160
1441
6
19
3.22
1.67
1.2
1.1
—
—
—
0
0
5
14
3.63
1.62
1.0
1.2
—
—
—
0
0
33
221
1.59
1.53
2.1
1.9
—
—
—
0
0
7
28
2.55
1.46
1.0
1.1
—
—
—
0
0
46
346
1.42
1.25
2.8
3.7
2710.2
1048.2
ng/l
0.73
38
284
186
1759
1.62
1.19
11.7
9.0
23.3
25.8
u/l
1.57
181
1699
0
36
0.00
1.15
0.0
1.2
—
—
—
0
0
16
97
1.70
1.10
3.6
1.8
—
—
—
0
0
161
1488
1.38
1.10
4.3
3.9
5.6
5.8
mmol/l
0.89
149
1372
159
1467
1.37
1.09
17.0
10.1
91.2
88.9
ml/min/173m2
0.55
132
1141
10
52
1.97
1.08
1.2
1.4
—
—
—
0
0
13
75
1.78
1.05
1.5
1.3
—
—
—
0
0
15
91
1.70
1.03
8.3
5.9
9.6
9.1
kpa
0.77
15
83
31
225
1.45
1.02
1.5
1.7
1.4
1.4
%
0.07
31
200
5
23
2.20
0.98
1.0
1.8
—
—
—
0
0
179
1693
1.45
0.98
20.1
11.5
23.7
21.4
mg/l
0.34
149
1287
17
109
1.61
0.97
2.7
3.3
69.1
76.0
ml/min/173m2
—
9
45
19
127
1.55
0.92
7.4
6.0
1.1
1.1
mmol/l
0.01
13
96
16
104
1.58
0.87
1.5
1.4
24.0
24.6
iu/l
—
10
86
8
44
1.85
0.87
2.5
1.2
—
—
—
0
0
6
32
1.90
0.82
1.0
1.3
—
—
—
0
0
35
272
1.35
0.80
1.7
1.7
461.1
28390292.1
pmol/l
0.50
30
236
8
48
1.69
0.79
1.3
1.6
—
—
—
0
0
19
134
1.46
0.74
7.4
5.8
4.9
5.1
kpa
0.53
19
123
5
25
2.02
0.73
1.6
1.8
—
—
—
0
0
56
472
1.26
0.71
1.6
1.4
0.4
2.1
u/ml
2.20
14
112
7
43
1.65
0.67
1.1
1.3
2.3
3.8
ug/l
—
7
38
15
103
1.49
0.67
2.2
1.5
—
—
—
0
0
17
122
1.43
0.62
2.4
2.4
664.3
3598.6
u/l
—
7
49
11
73
1.54
0.57
1.4
1.7
—
—
—
0
0
57
494
1.21
0.56
5.1
3.2
15.2
44.9
ng/l
1.74
37
301
9
59
1.55
0.55
1.1
1.2
—
—
—
0
0
13
180
0.70
0.54
2.2
1.6
—
—
—
0
0
19
144
1.35
0.53
3.8
3.4
—
—
—
0
0
36
302
1.23
0.48
3.3
3.6
84.1
230.9
ng/l
1.31
26
206
8
116
0.68
0.47
1.8
1.3
—
—
—
0
0
5
32
1.58
0.42
1.8
1.9
—
—
—
0
0
14
105
1.36
0.42
1.2
1.4
—
—
—
0
0
8
58
1.39
0.42
1.5
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
23
189
1.24
0.38
1.4
3.0
16.8
6.2
umol/l
0.43
17
152
5
37
1.36
0.37
1.2
1.1
—
—
—
0
0
32
370
0.84
0.36
1.9
2.8
280.3
4956.7
umol/l
1.58
27
320
43
380
1.17
0.35
3.2
3.8
17.8
11.6
mg/mmol
0.24
25
244
29
337
0.84
0.34
2.9
2.1
—
—
—
0
0
7
52
1.36
0.31
1.3
1.3
—
—
—
0
0
15
122
1.25
0.28
1.5
2.1
14.1
11.6
nmol/l
0.40
15
114
14
171
0.81
0.27
1.7
1.5
—
—
—
0
0
11
86
1.29
0.26
8.3
2.3
0.1
0.1
e6/l
0.09
11
81
33
370
0.87
0.26
3.1
2.3
—
—
—
0
0
14
170
0.81
0.26
2.6
1.8
—
—
—
0
0
160
1557
1.13
0.25
4.1
3.8
4.6
4.6
mmol/l
0.14
154
1460
153
1486
1.12
0.25
3.8
3.4
1.2
1.2
mmol/l
0.14
141
1377
65
607
1.10
0.23
6.1
3.3
—
—
—
0
0
5
38
1.32
0.23
3.0
1.5
—
—
—
0
0
15
126
1.21
0.21
1.1
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
3.0
—
—
—
0
0
0
10
0.00
0.21
0.0
3.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
23
203
1.15
0.20
3.3
2.5
0.6
0.7
ug/l
0.76
17
130
19
216
0.87
0.18
2.7
1.9
—
—
—
0
0
7
60
1.17
0.18
1.0
1.6
—
—
—
0
0
143
1395
1.08
0.17
5.5
4.8
37.9
38.8
mmol/mol
0.52
137
1308
40
429
0.92
0.16
6.3
3.3
0.0
0.0
estimate
0.50
16
158
10
83
1.22
0.15
2.0
1.4
269.0
294.7
miu/ml
—
5
43
16
141
1.15
0.14
8.0
6.5
—
—
—
0
0
157
1547
1.06
0.10
4.1
3.7
1.5
1.5
mmol/l
0.08
149
1437
52
498
1.06
0.10
1.8
1.8
—
—
—
0
0
5
45
1.11
0.10
1.8
1.9
—
—
—
0
0
5
46
1.09
0.09
1.8
1.9
—
—
—
0
0
10
87
1.16
0.09
1.9
1.4
—
—
—
0
0
10
87
1.16
0.09
1.9
1.4
—
—
—
0
0
10
87
1.16
0.09
2.0
1.4
—
—
—
0
0
10
87
1.16
0.09
1.9
1.4
—
—
—
0
0
31
329
0.93
0.09
1.4
1.5
—
—
—
0
0
6
57
1.05
0.08
1.0
1.2
—
—
—
0
0
6
58
1.04
0.08
1.0
1.2
—
—
—
0
0
5
62
0.80
0.08
1.0
1.6
—
—
—
0
0
7
80
0.87
0.07
1.4
1.7
—
—
—
0
0
28
268
1.05
0.05
4.3
4.0
19.5
21.9
%
0.47
13
121
30
291
1.04
0.02
1.3
1.3
30.4
32.2
iu/ml
—
7
91
158
1571
1.02
0.02
4.5
4.1
2.8
2.8
mmol/l
0.27
151
1465
29
283
1.03
0.01
1.1
1.3
1.0
10.5
u/ml
—
10
114
10
97
1.03
0.00
2.0
1.5
—
—
—
0
0
134
1345
0.99
0.00
4.0
3.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
15.1
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
5.1
—
1.2
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_BINOCUMOVNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVNAS | 1.577 [1.15, 2.17] | 0.005 |
| Birth year | 0.991 [0.98, 1.0] | 0.051 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 658 females with H7_BINOCUMOVNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVNAS | 2.058 [1.46, 2.9] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.023 |
During the follow-up period (1.1.1998 — 31.12.2019), 70 out of 582 males with H7_BINOCUMOVNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_BINOCUMOVNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.113% | 0.431% |
| 5 | 0.795% | 2.599% |
| 10 | 1.949% | 6.692% |
| 15 | 3.791% | 11.912% |
| 20 | 6.634% | 18.919% |
Relationships between endpoints
↥Index endpoint: H7_BINOCUMOVNAS – Other and unspecified disorders of binocular movement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data